Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Lenvatinib is an emerging multi-kinase inhibitor with a preferential anti-angiogenic activity, which has shown efficacy in the treatment of renal cell carcinoma, differentiated thyroid cancer and hepatocellular carcinoma. It inhibits vascular endothelial growth factor receptor family (VEGFR1-3), fibroblast growth factor receptor family (FGFR1-4), platelet-derived growth factor receptor-alpha (PDGFRα), tyrosine-kinase receptor (KIT) and rearranged during transfection receptor (RET). In this review we have evaluated the development from bench to bedside of lenvatinib. PubMed, MEDLINE and clinicaltrials.gov are the sources of data. Furthermore, the preclinical in vitro and in vivo data, as well as efficacy and toxicity results of lenvatinib in the clinic, are presented and discussed. Treatment with lenvatinib causes side effects (hypertension, proteinuria, fatigue and diarrhea), which are predominantly related to the inhibition of angiogenesis. For these reasons, the identification of biomarkers of efficacy and resistance to lenvatinib is a key challenge in order to select responsive patients. This review provides an overview on lenvatinib's clinical use, perspectives and indications for future development.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502442PMC
http://dx.doi.org/10.2147/CMAR.S188316DOI Listing

Publication Analysis

Top Keywords

growth factor
12
future development
8
treatment lenvatinib
8
factor receptor
8
receptor family
8
lenvatinib
6
lenvatinib molecule
4
molecule versatile
4
versatile application
4
application preclinical
4

Similar Publications

Background: Ovarian cancer remains the most lethal gynecological cancer, with fewer than 50% of patients surviving more than five years after diagnosis. This study aimed to analyze the global epidemiological trends of ovarian cancer from 1990 to 2021 and also project its prevalence to 2050, providing insights into these evolving patterns and helping health policymakers use healthcare resources more effectively.

Methods: This study comprehensively analyzes the original data related to ovarian cancer from the GBD 2021 database, employing a variety of methods including descriptive analysis, correlation analysis, age-period-cohort (APC) analysis, decomposition analysis, predictive analysis, frontier analysis, and health inequality analysis.

View Article and Find Full Text PDF

Background: A secondary Pasteurella multocida (Pm) infection following Mycoplasma ovipneumoniae (Mo) challenge in sheep results in severe respiratory disease. Scavenger receptor A (SRA) is a key phagocytic receptor on macrophages, which facilitates microbial clearance. However, the role of sheep SRA in Mo-associated secondary Pm infection is less understood.

View Article and Find Full Text PDF

Background: The roles of long non-coding RNAs (lncRNAs) in the progression of various human tumors have been extensively studied. However, their specific mechanisms and therapeutic potential in Triple-Negative Breast Cancer (TNBC) remain to be fully elucidated.

Materials And Methods: The qRT-PCR assay was utilized to assess the relative mRNA levels of TFAP2A-AS1, PHGDH, and miR-6892.

View Article and Find Full Text PDF

Drought stress is the most vulnerable abiotic factor affecting plant growth and yield. The use of silicic acid as seed priming treatment is emerging as an effective approach to regulate maize plants susceptibility to water stress. The study was formulated for investigating the effect of silicic acid seed priming treatment in modulating the oxidative defense and key physio-biochemical attributes of maize plants under drought stress conditions.

View Article and Find Full Text PDF

Immunogenic cell death (ICD) is a type of cell death sparking adaptive immune responses that can reshape the tumor microenvironment. Exploring key ICD-related genes in bladder cancer (BLCA) could enhance personalized treatment. The Cancer Genome Atlas (TCGA) BLCA patients were divided into two ICD subtypes: ICD-high and ICD-low.

View Article and Find Full Text PDF